Table 1.
Association Between PD-L1 Expression with Clinicopathological and Glycolytic Characteristics in Primary Lung Adenocarcinoma
| Characteristics | Total | PD-L1 Expression | ||
|---|---|---|---|---|
| Negative (n=43) | Positive (n=30) | P-value | ||
| Age (years) | 61.5 ± 8.6 | 60.4 ± 7.8 | 63.1 ± 9.6 | 0.187 |
| Gender | 0.544 | |||
| Male | 31 | 17 | 14 | |
| Female | 42 | 26 | 16 | |
| TNM stage | 0.002 | |||
| I+II | 49 | 35 | 14 | |
| III+IV | 24 | 8 | 16 | |
| Tumor size (mm) | 27.6 ± 13.2 | 23.9 ± 9.9 | 33.0 ± 15.6 | 0.003 |
| Tumor differentiation | 0.001 | |||
| Well/Moderate | 43 | 32 | 11 | |
| Poor | 30 | 11 | 19 | |
| CEA (ng/mL) | 3.1 (2.2, 6.4) | 2.6 (1.9, 5.5) | 4.0 (2.4, 9.9) | 0.070 |
| Ki67 | 10.0 (5.0, 25.0) | 10.0 (3.0, 25.0) | 17.5 (10.0, 40.0) | 0.040 |
| PD-1 | 4.3 ± 2.4 | 4.6 ± 2.1 | 4.0 ± 2.9 | 0.340 |
| GLUT-1 | 6.1 ± 2.2 | 5.3 ± 1.9 | 7.3 ± 2.2 | <0.0001 |
| HK-II | 5.5 ± 2.3 | 4.6 ± 2.0 | 6.7 ± 2.2 | <0.0001 |
| SUVmax | 8.2 ± 5.2 | 5.7 ± 4.0 | 11.8 ± 4.5 | <0.0001 |
| MTV (cm3) | 3.8 (1.9, 5.8) | 3.0 (1.6, 5.4) | 4.2 (2.0, 9.6) | 0.118 |
| TLG (cm3) | 14.0 (5.8, 36.6) | 8.0 (4.0, 24.0) | 35.5 (14.0, 62.8) | <0.0001 |
Abbreviations: PD-L1, programmed death ligand-1; CEA, carcino-embryonic antigen; PD-1, programmed death-1; GLUT-1, glucose transporter 1; HK-II, hexokinase II; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.